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Tumor spread to distant organs is the most serious consequence of melanoma, as only 10–20% of stage IV
patients respond to current chemotherapies. Tumor sensitivity to alkylating agents is affected by the activity of
cellular DNA repair proteins, such as O6-methylguanine DNA methyltransferase (MGMT) and the DNA
mismatch repair proteins. Chemosensitivity may be enhanced by reduced MGMT activity, but the frequency of
MGMT promoter silencing through hypermethylation is unknown in distant melanoma metastases. The
frequency and significance of microsatellite instability (MSI) in metastatic melanoma is also unclear, and it has
been suggested that MSI frequency increases during the metastatic process. We undertook an analysis of 84
melanoma metastases from 47 patients. MGMT methylation was detected using methylation-specific PCR in 26
of the 84 metastases (31%), but there was discordance between individual metastases from the same patient.
Therefore, as a result of this variation, MGMT methylation may have only limited value as a predictor of
chemosensitivity. High MSI involving mononucleotide repeat markers was not found. Low MSI was detected in
five of 50 metastases (10%) and only one of the five metastases also had MGMT methylation. These results
demonstrate that in contrast to some previous reports, these tumors have a low frequency of MSI.
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INTRODUCTION
Metastatic melanoma is an important cause of cancer
mortality, particularly in Caucasian people living in areas of
high sunlight exposure. Treatment of metastatic melanoma is
based on chemotherapy with the alkylating agents dacarbazine
or temozolamide (Eggermont and Kirkwood, 2004). Surgical
resection of distant metastatic disease sites is more frequently
performed in melanoma than in other tumor types because
long-term survival occasionally occurs following resection of
all apparent disease. Resection also relieves local complica-
tions such as bleeding or bowel obstruction due to metastases
in the small intestine (Thompson and Morton, 2004).
The efficacy of alkylating agents in the treatment of
melanoma is based on widespread DNA damage, which
signals cell death through apoptosis. To some extent,
cytotoxic drug sensitivity is determined by the activity of
cellular DNA repair proteins, such as O6-methylguanine
DNA methyltransferase (MGMT), and the DNA mismatch
repair proteins. Functional mismatch repair mediates the
cytotoxic effect of these drugs, whereas active MGMT can
counteract them by removing alkylating adducts from the O6-
position of guanine. It has long been recognized that
inhibiting the activity of the MGMT enzyme may enhance
the efficacy of alkylating chemotherapy (Dolan et al., 1990).
Inhibitors of MGMT such as O6-benzylguanine and O6-4-
bromothenyl-guanine are being investigated in clinical trials
(Friedman et al., 2000). The MGMT gene can be silenced by
promoter methylation in many cancers, but its frequency in
primary melanoma is thought to be low, at 11% (Esteller
et al., 1999). However, the frequency of MGMT methylation
in distant melanoma metastases has not yet been established.
Defective mismatch repair in cancer leads to widespread
DNA replication errors, which are particularly evident in
repetitive DNA sequences, such as microsatellites, and can
be detected using a standardized test from tumor DNA
(Dietmaier et al., 1997; Boland et al., 1998). In sporadic
colorectal cancers, the high microsatellite instability (MSI)
phenotype is present in about 10% of patients, predominantly
as a result of the MLH1 mismatch repair gene silencing
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through promoter hypermethylation (Kane et al., 1997). The
biological defect causing the low MSI (MSI-L) phenotype, on
the other hand, is not so well understood. Early reports
established that the frequency of MSI in primary melanoma
ranges from 2 to 20% (Peris et al., 1995; Quinn et al., 1995;
Tomlinson et al., 1996). Subsequent studies have suggested
that the frequency of MSI in melanoma increases during the
metastatic process, up to 38% in a group of regional and
distant metastases (Palmieri et al., 2000) and 77% in lymph
node metastases (Richetta et al., 2001). The reinterpretation
of the literature indicates that most MSI in melanoma involves
instability of the dinucleotide repeats, which therefore is
closer to the definition of MSI-L. However, there are a limited
number of studies addressing distant organ metastases.
Furthermore, no previous studies have addressed multiple
distant organ metastases from the same patient.
Although no clear biological difference has yet been found
between MSI-L and microsatellite stable tumors, we and
others have shown that the MSI-L phenotype is associated
with an MGMT defect in colorectal cancer (Whitehall et al.,
2001; Kohonen-Corish et al., 2005). This raised the intriguing
hypothesis that this may also be the case in melanoma, given
the potential importance of both types of alterations in the
metastatic process. Therefore, we undertook an analysis of
MGMT promoter methylation and MSI in metastatic mela-
noma. MGMT hypermethylation was determined with
methylation-specific PCR and MSI status was analyzed with
at least six microsatellite markers, including the standardized
panel used in colorectal cancer.
RESULTS
Analysis of MGMT promoter hypermethylation
We detected MGMT hypermethylation in 31.0% (26/84) of
the tumors, using methylation-specific PCR. In five of these
patients, methylation was also found in the matched control
DNA specimen prepared from the resected tissue outside the
tumor margin. The 22 patients who had at least one
methylated tumor are listed in Table 1. The organ sites with
methylated tumors included the lung (six patients), liver
(two), small intestine (two), rectus muscle (one), brain (two),
mesentery (one), and pancreas (one). Three methylated
specimens were derived from subcutaneous metastases and
eight from lymph nodes. For four organ sites, where 10 or
more specimens were analyzed, methylation frequency was
highest in the lymph node metastases (47.5%) and lowest in
the small intestine (12.5%) (Table 2). Seven of the 22 patients
had a single metastasis analyzed. Eleven patients had two to
four metastases but only one methylated tumor. Four patients
had two methylated tumors, out of a total of two to four
metastases analyzed. In each of these four cases, the
methylated tumors were resected in two separate operations.
Four patients had two metastases synchronously resected in
the same operation that showed discordant results (Patients 7,
9, 21, and 22).
Analysis of MSI
A subset of 50 metastases were initially available for MSI
analysis. We observed MSI in five of the 50 specimens
Table 1. Organ sites of the melanoma metastases
showing MGMT methylation or MSI
Patient
Site of methylated
melanoma metastases
Site of unmethylated
melanoma metastases
1 Lung Lung/pleura
2 Lung
3 Lung
4 Lung
5 Lung, subcutaneous metastasis
6 Lung
7 Liver1 Skeletal muscle1
8 Liver
9 Small intestine, pelvic
lymph node1
Inguinal lymph node1
10 Small intestine Small intestine
11 Skeletal muscle Lung
12 Brain Subcutaneous metastasis,
inguinal lymph nodes
13 Brain Lung
14 MesenteryMSI Small intestine
15 Pancreas Retroperitoneal lymph node
16 Subcutaneous metastasis,
axillary lymph node
Subcutaneous metastasis,
dermal metastasis
17 Subcutaneous metastasis,
inguinal lymph node
Lung
18 Axillary lymph node Axillary lymph node
19 Axillary lymph node
20 Inguinal lymph node
21 Hilar lymph node1 Hilar lymph node1, small
intestine2, lymph node2
22 Mediastinal lymph node1 Lung1, MSI
23 BrainMSI, lymph node
24 LungMSI, dermal metastasis
25 ColonMSI, small intestine
1 and 2Metastases resected synchronously.
MSIPatients 14, 22, 23, 24, and 25 each had only one metastasis showing
MSI with the D9S161 marker.
Table 2. Frequency of MGMT methylation in the main
sites of melanoma metastases analyzed
MGMT methylated MGMT unmethylated
Site No. (%) No. (%)
Lung 6 (37.5) 10 (62.5)
Small intestine 2 (12.5) 14 (87.5)
Lymph nodes 8 (47.5) 9 (52.5)
Subcutaneous/dermal 3 (30.0) 7(70.0)
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studied (10.0%) using the D9S161 marker (Figure 1), each
from a different patient (Table 1). Only one of these tumors in
patient no. 14 also showed MGMT methylation (P¼0.99,
Fisher’s exact test). Each patient had at least one other
metastasis with no MSI. Metastases demonstrating MSI were
from four sites, lung (two), colon (one), brain (one), and
mesentery (one). No cases demonstrated MSI using the
mononucleotide markers, and only one of the five tumors
also showed mild instability with a dinucleotide marker from
the colon cancer microsatellite panel.
DISCUSSION
Hypermethylation of gene promoters is an epigenetic process
through which tumor suppressor genes can become dysfunc-
tional and hence cancer promoting. Methylation of MGMT is
associated with a poor outcome in non-small-cell lung
cancer (Brabender et al., 2003). On the other hand,
chemosensitivity to alkylating agents may be enhanced by
inactivation of MGMT, as shown in glioma and diffuse large
B-cell lymphoma (Esteller et al., 2000, 2002). In melanoma,
low MGMT expression prior to treatment also tends to
correlate with better chemotherapy response (Ma et al.,
2003), but until now, the importance of MGMT promoter
methylation has not been assessed in distant metastases. This
study has shown that MGMT methylation occurs in about
31% of distant melanoma metastases. This percentage
compares very well with the recent findings by Hoon et al.
(2004), who found 34% MGMT methylation in a series of 86
tumors from 44 stage III/IV cutaneous melanoma patients.
However, we have also shown that in stage IV patients with
multiple distant metastases, methylation was not uniformly
present in all tumors. There was no prevalence of methylation
in any particular organ site, although it was striking that only
two out of 16 metastases occurring in the small intestine were
methylated. Therefore, it would be difficult to predict, based
on the analysis of one resected tumor, which patients are
likely to respond to chemotherapy. In five patients, methyla-
tion was also detected in the normal tissue adjacent to the
tumor, which could be due to small clusters of tumor cells
that were not detected in the histopathology review of slides.
Alternatively, it is possible that MGMT methylation is an early
epigenetic change, as discussed by Brabender et al. (2003),
who made similar findings in primary lung cancer.
The biological significance of MGMT methylation in
carcinogenesis is currently under investigation. It has been
hypothesized that inactivation of the MGMT gene in sporadic
colorectal cancer can overload the mismatch repair system
due to accumulation of DNA mispairs, which can result in a
mild mutator phenotype, and is characterized by MSI-L
(Whitehall et al., 2001). Although the definition of MSI-L in
sporadic colorectal cancer has been questioned (Tomlinson
et al., 2002), there is now emerging evidence that MSI-L
tumors form a distinct molecular group when gene expression
data from microarray experiments are analyzed using
principal components analysis (Mori et al., 2003). We have
also recently shown that MSI-L is a distinct phenotype in
stage C colon cancer, with an adverse prognosis (Kohonen-
Corish et al., 2005). Therefore, it was of interest to determine
whether there was any association between these two
phenotypes in metastatic melanoma, where the frequency
of MSI has been reported to range from 19 to 77% (Tomlinson
et al., 1996; Palmieri et al., 2000; Kroiss et al., 2001; Richetta
et al., 2001). As there is considerable variation in the
microsatellite markers used in analyzing melanoma MSI,
we decided to test the same microsatellite panel that was
originally used to define the association between MGMT
methylation and MSI-L in colorectal cancer (Whitehall et al.,
2001). This was supplemented by the dinucleotide marker
D9S161, which has been reported as a sensitive marker
for detecting loss of heterozygosity and for defining a subset
of melanomas with high metastatic potential (Puig et al.,
2000).
Altogether, the five tumors analyzed here displayed clear
instability with D9S161 (Figure 1). Only one of these
specimens also had a methylated MGMT promoter. The
D9S161 marker is located on chromosome 9 in the region
implicated in melanoma carcinogenesis. It is possible that
there are cancer-specific differences between the various
microsatellites used in detecting MSI. The chromosome 9
markers may be more sensitive in melanoma, although these
were not used in at least one previous study that reported the
highest frequency (77%) of MSI in melanoma metastases
(Richetta et al., 2001). In any case, the overall frequency of
MSI-L detected here was only 10%, and therefore our results
do not support the hypothesis that MSI is a significant factor
during the progression of melanoma to distant organ
metastases. However, it cannot be excluded that once the
biology of this phenotype is better understood, new
diagnostic tests or markers will emerge that will define a
wider extent of this subset of metastatic melanoma. On the
other hand, our results also suggest that the type of instability
involved in melanoma is not likely to be high microsatellite
instability, which is characterized by instability in the
mononucleotide repeats. Another laboratory has reported a
21% frequency of high MSI in metastatic melanoma, but their
definition included all tumors that displayed instability with
any two unstable markers, not just with mononucleotide
markers (Palmieri et al., 2003).
a b
Normal
tissue
Melanoma
metastasis
Size (bp) 125 127 109 115 125
Figure 1. Analysis of the dinucleotide repeat D9S161 from two patients
with metastatic melanoma (lung) and their matching normal lung tissue. MSI
is seen as the presence of extra peaks in the tumor tissue as indicated by
arrows. (a) Expected allele 125 bp and extra allele in tumor 127 bp;
(b) expected alleles 125 and 115 bp and extra allele 109 bp.
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In conclusion, the results establish the frequency of
MGMT methylation in almost one-third of distant melanoma
metastases. However, we observed discordant results, which
is likely to limit the potential value of MGMT methylation as
a predictor of chemosensitivity. We have further shown that
these tumors have a low frequency of MSI, and therefore we
were unable to demonstrate an association between MGMT
methylation and MSI-L in metastatic melanoma with the
microsatellite marker panel used here.
MATERIALS AND METHODS
Patients and specimens
The Sydney Melanoma Unit database contains details of surgical
resections for all patients attending the Unit. From the database,
patients who had undergone resection of distant metastatic
melanoma at the Royal Prince Alfred Hospital between 1996 and
2001 were identified. Patients who had surgery at other institutions
were excluded. Of the 47 patients for whom suitable tissue
specimens could be retrieved, 18 had one metastasis surgically
removed, and 22 patients had two metastases and seven patients had
three to four metastases resected. The metastatic sites included the
lung (16 metastases), small intestine (16), liver (five), spleen (three),
muscle (three), brain (four), adrenal gland (two), stomach (one),
colon (one), pancreas (one), pelvis (two), and omentum/mesentery
(three). Also, 17 lymph node metastases and 10 subcutaneous
metastases were included. Of the 29 patients with multiple
metastases, 11 had them resected in the same operation, whereas
the rest had two (16 patients) or three to four (two patients)
operations, most over a 1- to 2-year period. This study had the
approval of the Ethics Review Committee of the Central Sydney Area
Health Service and was exempted from obtaining informed consent
from the patients because only archival tumor specimens were used.
Archival hematoxylin and eosin sections of melanoma metastases
were first re-evaluated by a pathologist and the most suitable blocks
from each patient were chosen for subsequent analysis. Tumor and
normal tissue areas were marked on the slides. Serial sections (4 mm)
were manually microdissected for tumor and matched normal tissue.
DNA was purified using the Puregene DNA Isolation Kit (Gentra,
Minneapolis, MN).
MSI analysis
The international reference panel of microsatellite markers BAT25/
40, D2S123, D5S346, D17S250, and MYCL1 (Boland et al., 1998),
as well as D9S161 (Puig et al., 2000), was analyzed. One primer
from each primer pair was synthesized with a 50 fluorescent tag. PCR
amplification was performed as described previously (Kohonen-
Corish et al., 2005). Fragments were visualized using ABI 310
Genetic Analyzer (Applied Biosystems, Foster City, CA) capillary
electrophoresis and the microsatellite patterns of the tumors were
compared with normal tissue from the same patient.
Methylation-specific PCR
Aliquots of about 1mg of the tumor and normal DNA specimens
were bisulfite-treated, as described previously (Herman et al., 1996).
For MGMT, each specimen was amplified, as described previously
(Kohonen-Corish et al., 2005), using primers specific for both the
methylated and the unmethylated promoter sequences (Esteller
et al., 1999; Harden et al., 2003). The predicted fragment size is 122
base pairs (bp) for the methylated PCR and 93 bp for the
unmethylated PCR. The MYOD1 primers, which do not contain
any CpG nucleotide sequences, were used for an internal reference
PCR to ensure integrity of each bisulfite-treated DNA specimen
(Brabender et al., 2003). PCR conditions were 951C (45 seconds),
571C (45 seconds), and 721C (60 seconds) for 40 cycles, with an
initial denaturation step at 951C for 12 minutes and final elongation
at 721C for 7 minutes. All methylation-specific PCR products were
visualized on 6% polyacrylamide gels.
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